FEMY
Femasys Inc.
There isn't enough reported data to score FEMY yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
FEMY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
FEMY's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FEMY PE Valuation
FEMY has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FEMY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect FEMY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
FEMY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$14.40 | +$2.00 |
| Q2 2025 | -$17.20 | -$0.40 |
| Q1 2025 | -$18.20 | -$1.20 |
| Q4 2024 | -$17.00 | +$1.60 |
| Q3 2024 | -$16.40 | +$3.20 |
| Q2 2024 | -$16.80 | +$2.60 |
| Q1 2024 | -$17.00 | +$2.40 |
| Q4 2023 | -$18.60 | +$0.60 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 188% for FEMY versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
FEMY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $331.8K | -19% |
| Q1 2026 | $424.9K | +25% |
| Q4 2025 | $813.4K | +40% |
| Q3 2025 | $729.4K | +31% |
| Q2 2025 | $409.3K | +85% |
| Q1 2025 | $341.3K | +26% |
| Q4 2024 | $581.6K | +173% |
| Q3 2024 | $554.9K | +127% |
FEMY's revenue is growing: $331,827 last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1527% | -586 points |
| Q1 2026 | -994% | +606 points |
| Q4 2025 | -568% | +244 points |
| Q3 2025 | -501% | +422 points |
| Q2 2025 | -941% | +1083 points |
| Q1 2025 | -1600% | -323 points |
| Q4 2024 | -812% | +1276 points |
| Q3 2024 | -922% | +748 points |
FEMY's operating margin was −1527% last quarter, down 586 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over FEMY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over FEMY on profitability, with a higher operating margin.
FEMY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | +$501.9K |
| Q1 2026 | -$4.2M | +$639.2K |
| Q4 2025 | -$4.3M | +$856.3K |
| Q3 2025 | -$5.6M | +$300.9K |
| Q2 2025 | -$4.4M | +$62.1K |
| Q1 2025 | -$4.9M | -$229.1K |
| Q4 2024 | -$5.2M | -$2.1M |
| Q3 2024 | -$5.9M | -$3M |
FEMY has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over FEMY on cash generation, producing positive trailing cash flow while its opponent burns cash.
FEMY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -14% | -548K shares |
| 1 year | +167% | +2.1M shares |
| 3 years | +468% | +2.8M shares |
| 5 years | +637% | +2.9M shares |
FEMY has 3M diluted shares, up 167% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | $161,761 |
| Q4 2024 | $30,093 |
| Q3 2024 | — |
| Q2 2024 | $6,593 |
| Q1 2024 | $24,067 |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over FEMY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FEMY Net Leverage
FEMY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
FEMY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 4.5 | Oversold |
FEMY's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FEMY PE vs Healthcare Sector
FEMY has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FEMY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 19% below |
| 20 week MA | $2.55 | 45% below |
| 50 week MA | $7.09 | 80% below |
| 100 week MA | $13.3 | 89% below |
| 200 week MA | $17.3 | 92% below |
FEMY is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over FEMY on trend strength, trading above more of its moving averages.
FEMY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $240.0 | $91.6 | -62% |
| 2022 | $91.6 | $18.6 | -80% |
| 2023 | $18.6 | $19.5 | +4.8% |
| 2024 | $19.5 | $22.6 | +16% |
| 2025 | $22.6 | $14.2 | -37% |
| 2026 YTD | $14.2 | $1.40 | -90% |
FEMY has finished lower in three of the last five years. It's down 90% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FEMY on returns for 2026, with the stronger performance.